Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment
Rising budget constraints and demands for healthcare services create additional complexity within the decision process for resource allocation. Innovations and scientific progress have been shown to be key drivers of the increase in healthcare expenditures (1). In the context of rising medical care costs and limited resources, Health Technology Assessment (HTA) was developed as a tool to inform decision-making and to provide the rationalization behind these decisions driving resource allocation and spending for health technology products. Furthermore, HTA agencies make the decision-making process more transparent. The HTA approach involves evaluating multiple aspects of a new product’s value in order to maximize health gain provided within the setting of limited resources.
KeywordsHealth technology assessment HAS IQWiG/G-BA NICE Cost-effectiveness
- Latimer N, Ramsey S, Briggs A (2017) Cost–effectiveness models for innovative oncology treatments: How different methodological approaches can be used to estimate the value of novel therapies. ISPOR, Boston, USGoogle Scholar
- Pomedli S (2010) HTA and access to cancer medicines. EuroObserver 12:7–9Google Scholar
- Schwarzer R, Siebert U (2009) Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. Int J Technol Assess Health Care 25:305–314CrossRefGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefGoogle Scholar
- Toumi M (2017) Introduction to Market Access for Pharmaceuticals. CRC Press, Boca RatonGoogle Scholar